Travere Therapeutics
NEWS
Retrophin, Inc. joins the National Organization for Rare Disorders, the European Organisation for Rare Diseases, and others worldwide to recognize Rare Disease Day® 2019.
Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York Cityon Thursday, February 28, 2019 at 3:30 p.m. ET.
Retrophin, Inc. announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the close of the U.S. financial markets.
Top-line readout of pivotal FORT Study in PKAN expected 3Q19
Dr. Dube brings proven track record of global leadership built upon significant commercial and operational success
Retrophin, Inc. today announced that Stephen Aselage, chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 at 11:00 a.m. PT (2:00 p.m. ET).
Retrophin, Inc. announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA nephropathy, a rare kidney disorder that often leads to end-stage renal disease
Top-line data anticipated in the third quarter of 2019
JOBS
IN THE PRESS